FHD-909

Foghorn Therapeutics secured $50 million in equity financing, extending its operational runway to mid-2028. This capital infusion will support the advancement of its oncology pipeline, including its lead program FHD-909, an oral SMARCA2 inhibitor for NSCLC, and novel degrader programs targeting CBP, EP300, and ARID1B. The financing, which includes common shares and warrants, was led by prominent biotech investors and signals strong confidence in Foghorn’s Gene Traffic Control® platform and innovative cancer therapies.